Measuring Efficacy and Safety of DTx

While there is debate around whether DTx should be held to a higher or lower standard than traditional drugs, it is clear that in order for these solutions to be successfully adopted, prescribed and reimbursed, they have to meet the evidence requirements of the different stakeholders, regardless of what these demands are.  How can we measure DTx efficacy and safety so that they are validated with uniform rigor across settings? Although regulatory frameworks are going to evolve to adapt to new technologies, the inherent conservatism of regulatory processes will probably make this a long and tedious journey; what can the industry do to accelerate the changes needed? Join this meeting with other senior leaders to discuss: